Human medicines European public assessment report (EPAR): Epidyolex, cannabidiol, Date of authorisation: 19/09/2019, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Date of authorisation: 26/09/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 17, Status: Authorised

Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation (EU) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations

Clinical Trials Information System (CTIS) bitesize talk: End of transition period and notifications including serious breach, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 October 2024, 15:30 (CEST) to 16 October 2024, 17:00 (CEST)

Information session on the pilot for expert panels' advice for orphan medical devices, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 September 2024, 14:00 (CEST) to 23 September 2024, 16:30 (CEST)

Compilation of Union procedures on inspections and exchange of information

Introduction to the Compilation of Union procedures on inspections and exchange of information